304
- Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, et al. Responsiveness of the
SF-36 and the Health Assessment Questionnaire disability index in a systemic sclerosis clini-
cal trial. J Rheumatol. 2005;32:832–40. - Ware Jr JE, Sherbourne CD. The MOS 36-Item Short Health Survey (SF-36) I. Conceptual
framework and item selection. Med Care. 1992;30:473–83. - Ware Jr JE, Kosinki M, Keller S. SF-36 physical and mental health summary scales: a user’s
manual. Boston: New England Medical Center Health Institute; 1994. - Danieli E, Airo P, Bettoni L, Cinquini M, Antonioli CM, Cavazzana I, et al. Health-related
quality of life measured by the short form in systemic sclerosis: correlations with indexes of
disease severity, disability, and depressive symptoms. Clin Rheumatol. 2005;24:48–54.
doi: 10.1007/s10067-004-0970-z. - Cosutta R, Zeni S, Soldi A, Colombelli P, Belotti Masserini A, Fantini F. Evaluation of qual-
ity of life in patients with systemic sclerosis by the SR-36 questionnaire (In Italian). Rheum.
2002;54:122–7. - McHorney CA, Ware JE, Raczek AE. The MOS 36-item short-form health survey (SF-36):
II. Psychometric and clinical validity in measuring physical and mental health constructs.
Med Care. 1993;31(3):247–63. - Khanna D. Measuring disease activity and outcomes in clinical trials. In: Varga J, Denton CP,
Wigley FM, editors. Scleroderma: from pathogenesis to comprehensive management.
New York: Springer; 2012. p. 661–72. - Brazier L, Roberts J, Deverill M. The estimation of a preference-based measure of health
from the SF-36. J Health Econ. 2002;21(2):271–92. - Khanna D, Furst DE, Wong WK, Tsevat J, Clements PJ, Park GS, Postlethwaite AE, Ahmed
M, Ginsburg S, Hays RD, Scleroderma Collagen Type 1 Study Group. Reliability, validity
and minimally important differences of the SF-6D in systemic sclerosis. Qual Life Res.
2007;16:1083–92. doi: 10.1007/s11136-007-9207-3. - Kallen MA, Mayes MD, Kriseman YL, de Achaval SB, Cox VL, Suarez-Almazor ME. The
symptom burden index: development and initial fi ndings from use with patients with sys-
temic sclerosis. J Rheumatol. 2010;37:1692–8. doi: 10.3899/jrheum.090504. - Silman A, Akesson A, Newman J, Henriksson H, Sandquist G, Nihill M, Palfrey S, et al.
Assessment of functional ability in patients with scleroderma: a proposed disability assess-
ment instrument. J Rheumatol. 1998;25(1):79–83. - Poole JL, Brower L. Validity of the scleroderma functional assessment questionnaire.
J Rheumatol. 2004;31:402–3. - Serednicka K, Smyth AE, Black CM, Denton CP. Using a self-reported functional score to
assess disease progression in systemic sclerosis. Rheumatology (Oxford). 2007;46(7):
1107–10. - Sjogren RW. Gastrointestinal motility disorders in scleroderma [review]. Arthritis Rheum.
1994;37:1265–82. - Lock G, Holstege A, Lang B, Scholmerich J. Gastrointestinal manifestations of progressive
systemic sclerosis. Am J Gastroenterol. 1997;92:763–71. - Nietert PJ, Mitchell HC, Bolster MB, Curran MY, Tilley BC, Silver RM. Correlates of
depression, including overall and gastrointestinal functional status, among patients with sys-
temic sclerosis. J Rheumatol. 2005;32:51–7. - Gliddon AE, Dore CJ, Maddison PJ, QUINS Trial Study Group. Infl uence of clinical features
on the health status of patients with limited cutaneous systemic sclerosis. Arthritis Rheum.
2006;55:473–9. - Khanna D, Hays RD, Park GS, Braun-Moscovici Y, Mayes MD, McNearney TA, et al.
Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instru-
ment. Arthritis Rheum. 2007;57:1280–6. - Khanna D, Hays RD, Maranian P, Seibold JR, Impens A, Mayes MD, et al. Reliability and
validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium
Gastrointestinal Tract Instrument. Arthritis Rheum. 2009;61:1257–63. doi: 10.1002/art.24730.
R.E. Pellar et al.